Spruce Biosciences (SPRB) Projected to Post Earnings on Monday

Key Points

• Spruce Biosciences is expected to report Q3 2026 results on November 9, with analysts forecasting a loss of $5.68 per share and revenue of $50 million. The earnings call is scheduled for November 11.
• The company previously missed earnings expectations, reporting a Q2 loss of $6.68 per share versus the $5.79 consensus estimate. Analysts project full-year and next-year losses of $25.53 and $1.83 per share, respectively.
• Despite the losses, analyst sentiment remains broadly positive: 11 analysts rate the stock Buy and one rates it Sell, producing a “Moderate Buy” consensus and an average price target of $158.33, well above its recent $46.39 price.

Spruce Biosciences (NASDAQ:SPRB - Get Free Report) is expected to announce its Q3 2026 resultson Monday, November 9th. Analysts expect Spruce Biosciences to post earnings of ($5.6756) per share and revenue of $50.00 million for the quarter. Investors may review the information on the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 11, 2026 at 9:30 AM ET.

Spruce Biosciences (NASDAQ:SPRB - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($6.68) EPS for the quarter, missing the consensus estimate of ($5.79) by ($0.89). On average, analysts expect Spruce Biosciences to post ($25.53) EPS for the current fiscal year and ($1.83) EPS for the next fiscal year.

Spruce Biosciences Price Performance

Spruce Biosciences stock opened at $46.39 on Monday. The stock has a market cap of $133.32 million, a P/E ratio of -1.17 and a beta of 3.25. The company has a quick ratio of 9.23, a current ratio of 9.23 and a debt-to-equity ratio of 0.05. Spruce Biosciences has a twelve month low of $38.06 and a twelve month high of $129.00. The company's 50-day moving average price is $50.01 and its two-hundred day moving average price is $55.99.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on SPRB shares. B. Riley Financial assumed coverage on Spruce Biosciences in a research report on Monday, July 13th. They issued a "buy" rating and a $160.00 target price on the stock. The Goldman Sachs Group upgraded Spruce Biosciences to an "overweight" rating in a research note on Thursday, August 13th. Citigroup reaffirmed a "market outperform" rating on shares of Spruce Biosciences in a report on Friday, September 18th. Guggenheim reiterated a "buy" rating and set a $104.00 price objective (down from $123.00) on shares of Spruce Biosciences in a research report on Monday, August 17th. Finally, HC Wainwright reissued a "buy" rating on shares of Spruce Biosciences in a report on Wednesday, August 26th. Eleven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $158.33.

Spruce Biosciences Company Profile

Spruce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for rare endocrine disorders. The company's research is centered on conditions in which abnormal hormone production or regulation creates significant health risks and limited treatment options.

Its lead investigational product is tildacerfont, an oral, selective corticotropin-releasing factor type 1 receptor antagonist. Spruce has studied tildacerfont as a potential treatment for congenital adrenal hyperplasia, a rare genetic disorder affecting the adrenal glands, and has evaluated its ability to reduce hormone imbalances associated with the disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.